Pharmacology, efficacy and safety of oral phosphate binders

Nature Reviews Nephrology

Volumn 7, Issue 10, 2011, Pages 578-589

  Hutchison, Alastair J ^a   Smith, Craig P ^b   Brenchley, Paul E C ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM SALT; CALCIUM ACETATE; CALCIUM CARBONATE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; MAGNESIUM SALT; PHOSPHATE BINDING AGENT; SEVELAMER; SEVELAMER CARBONATE;

BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; DRUG BINDING; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT PREFERENCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; REVIEW;

ACETATES; ANIMALS; CALCIUM COMPOUNDS; CHELATING AGENTS; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPHOSPHATEMIA; INTESTINAL ABSORPTION; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES, PROXIMAL; LANTHANUM; PARATHYROID HORMONE; PHOSPHATES; POLYAMINES; RENAL DIALYSIS;

EID: 80053357718     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.112     Document Type: Review

References (132)

1. Cancer Research UK. Ovarian cancer survival statistics [online], http://info.cancerresearchuk.org/cancerstats/types/ovary/survival (2011).
2. Ansell, D.; et al. UK Renal Registry 12th Annual Report 117-144 (The Renal Association, Bristol, UK, 2009).
3. Block, G. A., Hulbert-Shearon, T. E., Levin, N. W. & Port, F. K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 31, 607-617 (1998).
4. Mathew, S.; et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J. Am. Soc. Nephrol. 19, 1092-1105 (2008).
5. Cozzolino, M., Ciceri, P., Volpi, E. M., Olivi, L. & Messa, P. G. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease. Blood Purif. 27, 338-344 (2009).
6. Hruska, K. A., Saab, G., Mathew, S. & Lund, R. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin. Dial. 20, 309-315 (2007).
7. Uribarri, J. Phosphorus additives in food and their effect in dialysis patients. Clin. J. Am. Soc. Nephrol. 4, 1290-1292 (2009).
8. Uribarri, J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin. Dial. 20, 295-301 (2007).
9. Zisman, A. L. & Wolf, M. Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 19, 335-342 (2010).
10. Kooienga, L. Phosphorus balance with daily dialysis. Semin. Dial. 20, 342-345 (2007).
11. Kolek, O. I.; et al. 1α, 25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G1036-G1042 (2005). (Pubitemid 41740608)
12. Larsson, T., Nisbeth, U., Ljunggren, O., Juppner, H. & Jonsson, K. B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 64, 2272-2279 (2003). (Pubitemid 37449564)
13. Gutiérrez, O.; et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16, 2205-2215 (2005). (Pubitemid 41716454)
14. Perwad, F.; et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146, 5358-5364 (2005). (Pubitemid 41653049)
15. Antoniucci, D. M., Yamashita, T. & Portale, A. A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 91, 3144-3149 (2006). (Pubitemid 44271770)
16. Liu, S.; et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17, 1305-1315 (2006). (Pubitemid 43673410)
17. Imanishi, Y.; et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 65, 1943-1946 (2004). (Pubitemid 38591047)
18. Shigematsu, T.; et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis. 44, 250-256 (2004). (Pubitemid 38962552)
19. Shimada, T.; et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab. 95, 578-585 (2009).
20. Fliser, D.; et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 18, 2600-2608 (2007).
21. Hsu, H. J. & Wu, M. S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am. J. Med. Sci. 337, 116-122 (2009).
22. Gutiérrez, O. M.; et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119, 2545-2552 (2009).
23. Gutiérrez, O. M.; et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584-592 (2008).
24. Ben-Dov, I. Z.; et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117, 4003-4008 (2007). (Pubitemid 350224109)
25. Komaba, H. & Fukagawa, M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 77, 292-298 (2009).
26. Koh, N.; et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem. Biophys. Res. Commun. 280, 1015-1020 (2001). (Pubitemid 32924441)
27. Komaba, H.; et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 77, 232-238 (2010).
28. Galitzer, H., Ben-Dov, I. Z., Silver, J. & Naveh-Many, T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77, 211-218 (2010).
29. Wang, Z.; et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 13, 1176-1184 (2007). (Pubitemid 47530630)
30. Adragão, T.; et al. A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrol. Dial. Transplant. 24, 997-1002 (2009).
31. Adragão, T.; et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol. Dial. Transplant. 19, 1480-1488 (2004). (Pubitemid 38786742)
32. Isakova, T.; et al. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 20, 388-396 (2009).
33. Wills, M. R. & Savory, J. Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia. Lancet 2, 29-34 (1983). (Pubitemid 13060461)
34. González-Revalder'a, J.; et al. Biochemical and hematological changes in low-level aluminum intoxication. Clin. Chem. Lab. Med. 38, 221-225 (2000).
35. Becaria, A., Campbell, A. & Bondy, S. C. Aluminum as a toxicant. Toxicol. Ind. Health 18, 309-320 (2002). (Pubitemid 38352147)
36. Rüster, M., Abendroth, K., Lehmann, G. & Stein, G. Aluminum deposition in the bone of patients with chronic renal failure-detection of aluminum accumulation without signs of aluminum toxicity in bone using acid solochrome azurine. Clin. Nephrol. 58, 305-312 (2002).
37. Jaffe, J. A., Liftman, C. & Glickman, J. D. Frequency of elevated serum aluminum levels in adult dialysis patients. Am. J. Kidney Dis. 46, 316-319 (2005). (Pubitemid 41040361)
38. Andrade, L. G.; et al. Dialysis encephalopathy secondary to aluminum toxicity, diagnosed by bone biopsy. Nephrol. Dial. Transplant. 20, 2581-2582 (2005). (Pubitemid 41548902)
39. Feith, G. W. Oral phosphate binders in patients with kidney failure. N. Engl. J. Med. 363, 989-990 (2010).
40. Slatopolsky, E., Weerts, C., Stokes, T., Windus, D. & Delmez, J. Alternative phosphate binders in dialysis patients: calcium carbonate. Semin. Nephrol. 6, 35-41 (1986).
41. Schaefer, K., Umlauf, E. & von Herrath, D. Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Am. J. Kidney Dis. 19, 460-464 (1992).
42. Stamatakis, M. K., Alderman, J. M. & Meyer-Stout, P. J. Influence of pH on in vitro disintegration of phosphate binders. Am. J. Kidney Dis. 32, 808-812 (1998). (Pubitemid 28516312)
43. Sheikh, M. S.; et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J. Clin. Invest. 83, 66-73 (1989). (Pubitemid 19048406)
44. Pflanz, S., Henderson, I. S., McElduff, N. & Jones, M. C. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol. Dial. Transplant. 9, 1121-1124 (1994). (Pubitemid 24254079)
45. Harris, D. C. & Yuill, L. Calcium alginate versus aluminum hydroxide in patients on hemodialysis. Nephron 65, 324-325 (1993). (Pubitemid 23268052)
46. Passlick, J., Wilhelm, M., Busch, T., Grabensee, B. & Ohnesorge, F. K. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD. Clin. Nephrol. 32, 96-100 (1989). (Pubitemid 19204971)
47. Takahashi, N.; et al. Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients. J. Am. Soc. Nephrol. 10, 1090-1094 (1999). (Pubitemid 29203097)
48. Birck, R., Zimmermann, E., Wassmer, S., Nowack, R. & van der Woude, F. J. Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study. Nephrol. Dial. Transplant. 14, 1475-1479 (1999). (Pubitemid 29241741)
49. Macia, M. & Coronel, F. Serum phosphate control: what about calcium salts of keto-amino acids? Nephrol. Dial. Transplant. 10, 2159-2160 (1995).
50. Schaefer, K., von Herrath, D., Asmus, G. & Umlauf, E. The beneficial effect of ketoacids on serum phosphate and parathyroid hormone in patients with chronic uremia. Clin. Nephrol. 30, 93-96 (1988).
51. Nilsson, P., Johansson, S. G. & Danielson, B. G. Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium. Nephron 37, 25-29 (1984). (Pubitemid 14152934)
52. Hutchison, A. J.; et al. Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations. Nephron 72, 52-58 (1996). (Pubitemid 26009471)
53. Hutchison, A. J., Merchant, M., Boulton, H. F., Hinchcliffe, R. & Gokal, R. Calcium and magnesium mass transfer in peritoneal dialysis patients using 1.25 mmol/L calcium, 0.25 mmol/L magnesium dialysis fluid. Perit. Dial. Int. 13, 219-223 (1993). (Pubitemid 23235971)
54. Meema, H. E., Oreopoulos, D. G. & Rapoport, A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int. 32, 388-394 (1987). (Pubitemid 17147886)
55. Montezano, A. C.; et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 56, 453-462 (2010).
56. Gorgels, T. G.; et al. Dietary magnesium, not calcium, prevents vascular calcification in a mouse model for pseudoxanthoma elasticum. J. Mol. Med. 88, 467-475 (2010).
57. Turgut, F.; et al. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int. Urol. Nephrol. 40, 1075-1082 (2008).
58. Autissier, V., Damment, S. J. & Henderson, R. A. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J. Pharm. Sci. 96, 2818-2827 (2007). (Pubitemid 47597830)
59. Damment, S. J. & Pennick, M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin. Pharmacokinet. 47, 553-563 (2008).
60. Damment, S. J. & Pennick, M. Systemic lanthanum is excreted in the bile of rats. Toxicol. Lett. 171, 69-77 (2007). (Pubitemid 46990669)
61. Persy, V. P., Behets, G. J., Bervoets, A. R., De Broe, M. E. & D'Haese, P. C. Lanthanum: a safe phosphate binder. Semin. Dial. 19, 195-199 (2006). (Pubitemid 43742655)
62. Altmann, P., Barnett, M. E. & Finn, W. F. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int. 71, 252-259 (2007). (Pubitemid 46160926)
63. Albaaj, F. & Hutchison, A. J. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. Expert Opin. Pharmacother. 6, 319-328 (2005). (Pubitemid 40305343)
64. Goldsmith, D. R., Scott, L. J., Cvetkovic, R. S. & Plosker, G. L. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs 68, 85-104 (2008). (Pubitemid 350275686)
65. Burke, S., Amin, N., Incerti, C., Plone, M. & Watson, N. Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. J. Clin. Pharmacol. 41, 193-198 (2001). (Pubitemid 32106059)
66. Burke, S. K., Slatopolsky, E. A. & Goldberg, D. I. RenaGel, a novel calcium-and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol. Dial. Transplant. 12, 1640-1644 (1997). (Pubitemid 27346290)
67. Wrong, O. & Harland, C. Sevelamer. Nephrol. Dial. Transplant. 23, 2108 (2008).
68. Plone, M. A., Petersen, J. S., Rosenbaum, D. P. & Burke, S. K. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin. Pharmacokinet. 41, 517-523 (2002). (Pubitemid 34804163)
69. Rosenbaum, D. P., Holmes-Farley, S. R., Mandeville, W. H., Pitruzzello, M. & Goldberg, D. I. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol. Dial. Transplant. 12, 961-964 (1997). (Pubitemid 27216318)
70. Burke, S. K., Amin, N. S., Incerti, C., Plone, M. A. & Lee, J. W. Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. J. Clin. Pharmacol. 41, 199-205 (2001). (Pubitemid 32106060)
71. Kays, M. B., Overholser, B. R., Mueller, B. A., Moe, S. M. & Sowinski, K. M. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am. J. Kidney Dis. 42, 1253-1259 (2003). (Pubitemid 37486770)
72. Pieper, A. K.; et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol. Dial. Transplant. 19, 2630-2633 (2004).
73. Delmez, J.; et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin. Nephrol. 68, 386-391 (2007). (Pubitemid 350258767)
74. Pai, A. B. & Shepler, B. M. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 29, 554-561 (2009).
75. Fan, S.; et al. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol. Dial. Transplant. 24, 3794-3799 (2009).
76. Chertow, G. M.; et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. 29, 66-71 (1997). (Pubitemid 27020797)
77. Al-Baaj, F., Speake, M. & Hutchison, A. J. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol. Dial. Transplant. 20, 775-782 (2005). (Pubitemid 40520656)
78. McIntyre, C. W.; et al. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4, 401-409 (2009).
79. Locatelli, F.; et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol. Dial. Transplant. 25, 574-581 (2010).
80. Johnson, D. W. Sevelamer versus calcium-based phosphate binders in chronic kidney disease: what should we conclude from the evidence to date? Nephrol. Dial. Transplant. 24, 2970-2972 (2009).
81. Navaneethan, S. D., Palmer, S. C., Craig, J. C., Elder, G. J. & Strippoli, G. F. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am. J. Kidney Dis. 54, 619-637 (2009).
82. Chertow, G. M., Burke, S. K. & Raggi, P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 62, 245-252 (2002). (Pubitemid 34754068)
83. Jamal, S. A., Fitchett, D., Lok, C. E., Mendelssohn, D. C. & Tsuyuki, R. T. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol. Dial. Transplant. 24, 3168-3174 (2009).
84. Sprague, S. M.; et al. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin. Nephrol. 72, 252-258 (2009).
85. Arenas, M. D.; et al. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J. Nephrol. 23, 683-692 (2010).
86. Suki, W. N.; et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 72, 1130-1137 (2007). (Pubitemid 47609037)
87. Wilson, R., Zhang, P., Smyth, M. & Pratt, R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr. Med. Res. Opin. 25, 3021-3028 (2009).
88. [No authors listed] KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 76, S1-S130 (2009).
89. Parham, R., Riley, S., Hutchison, A. & Horne, R. Patients' satisfaction with information about phosphate-binding medication. J. Ren. Care 35 (Suppl. 1), 86-93 (2009).
90. Chiu, Y. W.; et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin. J. Am. Soc. Nephrol. 4, 1089-1096 (2009).
91. Arenas, M. D.; et al. Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control [Spanish]. Nefrologia 30, 522-530 (2010).
92. Hutchison, A. J. & Laville, M. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol. Dial. Transplant. 23, 3677-3684 (2008).
93. Hutchison, A. J.; et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin. Pract. 102, c61-c71 (2006). (Pubitemid 43087563)
94. Hutchison, A. J., Barnett, M. E., Krause, R. & Siami, G. A. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis. Clin. Nephrol. 71, 286-295 (2009).
95. Hutchison, A. J., Barnett, M. E., Krause, R., Kwan, J. T. & Siami, G. A. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin. Pract. 110, c15-c23 (2008).
96. [No authors listed] Sevelamer: constipation and occlusion. Complications, sometimes fatal. Prescrire Int. 17, 111 (2008).
97. Madan, P., Bhayana, S., Chandra, P. & Hughes, J. I. Lower gastrointestinal bleeding: association with sevelamer use. World J. Gastroenterol. 14, 2615-2616 (2008). (Pubitemid 352037760)
98. Friedman, E. A. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin. J. Am. Soc. Nephrol. 1, 704-709 (2006).
99. Moe, S. M. & Chertow, G. M. The case against calcium-based phosphate binders. Clin. J. Am. Soc. Nephrol. 1, 697-703 (2006).
100. Bushinsky, D. A. Phosphate binders: hold the calcium? Clin. J. Am. Soc. Nephrol. 1, 695-696 (2006).
101. Spiegel, D. M. The role of magnesium binders in chronic kidney disease. Semin. Dial. 20, 333-336 (2007).
102. O'Donovan, R., Baldwin, D., Hammer, M., Moniz, C. & Parsons, V. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet 1, 880-882 (1986).
103. Spiegel, D. M. & Farmer, B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodial. Int. 13, 453-459 (2009).
104. Spiegel, D. M., Farmer, B., Smits, G. & Chonchol, M. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J. Ren. Nutr. 17, 416-422 (2007). (Pubitemid 350001351)
105. Baradaran, A. & Nasri, H. Correlation of serum magnesium with serum parathormone levels in patients on regular hemodialysis. Saudi J. Kidney Dis. Transpl. 17, 344-350 (2006).
106. Wei, M., Esbaei, K., Bargman, J. & Oreopoulos, D. G. Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patients on dialysis: a literature review. Perit. Dial. Int. 26, 366-373 (2006). (Pubitemid 44340006)
107. Navarro, J. F., Mora, C. & Garcia, J. Serum magnesium and parathyroid hormone levels in dialysis patients. Kidney Int. 57, 2654 (2000). (Pubitemid 30340767)
108. de Francisco, A. L.; et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol. Dial. Transplant. 25, 3707-3717 (2010).
109. Hutchison, A. J.; et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin. Pract. 100, c8-c19 (2005). (Pubitemid 40674602)
110. Finn, W. F. & SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin. Nephrol. 65, 191-202 (2006). (Pubitemid 43337998)
111. Hutchison, A. J.; et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin. Pract. 102, c61-c71 (2006). (Pubitemid 43087563)
112. Molony, D. A. & Murthy, B. Accumulation of metals and minerals from phosphate binders. Blood Purif. 23 (Suppl. 1), 2-11 (2005). (Pubitemid 44681102)
113. Lacour, B.; et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 67, 1062-1069 (2005). (Pubitemid 41623331)
114. Damment, S. J. Enlightenment on liver lanthanum exposure. Kidney Int. 70, 1372-1373 (2006).
115. D'Haese, P. C.; et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. Suppl. 63, S73-S78 (2003).
116. Brezina, B., Qunibi, W. Y. & Nolan, C. R. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int. Suppl. S39-S45 (2004). (Pubitemid 39121058)
117. Ketteler, M.; et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin. J. Am. Soc. Nephrol. 3, 1125-1130 (2008).
118. Pierce, D.; et al. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol. Dial. Transplant. 26, 1615-1621 (2010).
119. Block, G. A., Brillhart, S. L., Persky, M. S., Amer, A. & Slade, A. J. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int. 77, 897-903 (2010).
120. Katai, K.; et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol. Dial. Transplant. 14, 1195-1201 (1999). (Pubitemid 29209307)
121. Takahashi, Y.; et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int. 65, 1099-1104 (2004). (Pubitemid 38251086)
122. Young, D. O., Cheng, S. C., Delmez, J. A. & Coyne, D. W. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit. Dial. Int. 29, 562-567 (2009).
123. Knip, M.; et al. Safety of high-dose nicotinamide: a review. Diabetologia 43, 1337-1345 (2000).
124. Kirchner, S.; et al. Luminal fructose inhibits rat intestinal sodium-phosphate cotransporter gene expression and phosphate uptake. Am. J. Clin. Nutr. 87, 1028-1038 (2008). (Pubitemid 351549250)
125. Hilfiker, H.; et al. Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc. Natl Acad. Sci. USA 95, 14564-14569 (1998). (Pubitemid 28549407)
126. White, K. E., Biber, J., Murer, H. & Econs, M. J. Chromosomal localization of two human genes involved in phosphate homeostasis: the type IIb sodium-phosphate cotransporter and stanniocalcin-2. Somat. Cell Mol. Genet. 24, 357-362 (1998). (Pubitemid 30194123)
127. Shibasaki, Y.; et al. Targeted deletion of the tybe IIb Na(+)-dependent Pi-co-transporter, NaPi-IIb, results in early embryonic lethality. Biochem. Biophys. Res. Commun. 381, 482-486 (2009).
128. Sabbagh, Y.; et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J. Am. Soc. Nephrol. 20, 2348-2358 (2009).
129. Marks, J.; et al. Intestinal phosphate absorption and the effect of vitamin D: a comparison of rats with mice. Exp. Physiol. 91, 531-537 (2006).
130. Savica, V.; et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J. Am. Soc. Nephrol. 20, 639-644 (2009).
131. Arenas, M. D.; et al. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J. Nephrol. 23, 525-534 (2010).
132. [No authors listed] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993).